Celltrion $068270.KS
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-35
RECRUITING2
READOUTS ≤12 MONTHS4
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| CT-P55 NCT06630559 |
P3 | Active, not recruiting | Plaque Psoriasis | 153 | 2026-02-18 (+3 mo) |
| Metformin NCT07093476 |
P3 | Recruiting | T2DM; Diabete Type 2 | 171 | 2026-12 |
| CT-P51 NCT06939595 |
P3 | Active, not recruiting | Non Squamous Non Small Cell Lung Cancer | 225 | 2027-02 |
| CT-P53 NCT05906992 |
P3 | Recruiting | Relapsing-remitting Multiple Sclerosis | 512 | 2027-02 |
| CT-P44(Daratumumab) NCT06952478 |
P3 | Active, not recruiting | Refractory or Relapsed Multiple Myeloma | 473 | 2027-03-08 (-8 mo) |